T1	Participants 137 156	chronic hepatitis C
T2	Participants 595 723	total of 517 HALT-C patients received peginterferon alfa-2a (90 microg/week); 532 received no additional treatment for 3.5 years
T3	Participants 944 977	Patients with cirrhosis (n = 427)
T4	Participants 1046 1078	patients with fibrosis (n = 622)
T5	Participants 1734 1781	in men, sexual health in a large patient cohort
